GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
P/E ratio for GeneDx Holdings Corp. (WGS)
P/E ratio as of 2023: -0.38
According to GeneDx Holdings Corp.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.38. At the end of 2022 the company had a P/E ratio of -0.16.
P/E ratio history for GeneDx Holdings Corp. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.38 |
| 2022 | -0.16 |
| 2021 | -1.96 |
| 2020 | 0.00 |
| 2019 | -75.95 |